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STUDY PROTOCOL Open Access
Effectiveness and cost-effectiveness of a
tailored text-message programme (MiQuit)
for smoking cessation in pregnancy: study
protocol for a randomised controlled trial
(RCT) and meta-analysis
Rachel Whitemore1,7* , Jo Leonardi-Bee2,7†, Felix Naughton3,7†, Stephen Sutton4,7†, Sue Cooper1,7, Steve Parrott5,7,
Catherine Hewitt5, Miranda Clark1,7, Michael Ussher6,7,8, Matthew Jones1, David Torgerson6 and Tim Coleman1,7
Abstract
Background: Smoking in pregnancy is a major international public health problem. Self-help support (SHS)
increases the likelihood of women stopping smoking in pregnancy and delivering this kind of support by text
message could be a cost-effective way to deliver SHS to pregnant women who smoke. SHS delivered by text
message helps non-pregnant smokers to stop but the currently available message programmes are not appropriate for
use in pregnancy.
A randomised controlled trial (RCT) has demonstrated the feasibility and acceptability of using a programme
called ‘MiQuit’ to text SHS support to pregnant women who smoke. Another pilot RCT has shown that it
would be feasible to run a larger, multi-centre trial within the UK National Health Service (NHS). The aim of
this third RCT is to complete MiQuit’s evaluation, demonstrating whether or not this is efficacious for smoking
cessation in pregnancy.
Methods/design: This is a multi-centre, parallel-group RCT. Pregnant women aged over 16 years, of less than
25 weeks’ gestation who smoke one or more daily cigarettes but smoked at least five daily cigarettes before
pregnancy and who understand written English and are being identified in 24 English antenatal care
hospitals. Participants are randomised to control or intervention groups in a 1:1 ratio stratified by gestation
(< 16 weeks versus ≥ 16 weeks). All participants receive a leaflet on stopping smoking during pregnancy; they
are also able to access standard NHS smoking cessation support. Intervention group women also receive the
12-week MiQuit programme of tailored, interactive text message, and self-help cessation support. Women are
followed up by telephone at 4 weeks after randomisation and 36 weeks’ gestation. The RCT will recruit 692
women (346 per group), enabling a 95% confidence interval for the difference in quit rates to be estimated
within ± 3%. To determine whether or not MiQuit helps pregnant smokers to stop, intervention group quit
rates from this trial will be combined with those from the two earlier trials in a Trial Sequential Analysis (TSA)
meta-analysis to derive a pooled efficacy estimate.
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© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Rachel.whitemore@nottingham.ac.uk
†Jo Leonardi-Bee, Felix Naughton and Stephen Sutton contributed equally to
this work.
1Division of Primary Care, University of Nottingham, Nottingham NG7 2RD,
UK
7UK Centre for Tobacco and Alcohol Studies, Nottingham, UK
Full list of author information is available at the end of the article
Whitemore et al. Trials          (2019) 20:280 
https://doi.org/10.1186/s13063-019-3341-4
(Continued from previous page)
Discussion: If effective, MiQuit will be a cheap, cost-effective method to help pregnant women to stop smoking.
Trial registration: ClinicalTrials.gov, ID: NCT03231553. Registered on 20 July 2017.
Keywords: Smoking cessation, Pregnancy, Self-help, Randomised controlled trial, Protocol
Background
As well as causing cancer, smoking is strongly associated
with increased pregnancy-specific risks of miscarriage,
stillbirth, prematurity, low birth weight, perinatal morbid-
ity and mortality, neo-natal and sudden infant death, [1]
poorer infant cognition and adverse infant behavioural
outcomes [2, 3]. Smoking in pregnancy is expensive to
health care services; in the UK in 2010 the annual
smoking-attributable maternal and infant health care costs
were estimated at up to £87.5 million [4]. In high-income
countries just over 10 to 25% of pregnant women smoke,
with highest rates seen amongst younger, socially disad-
vantaged women, [5–9] and rates are also increasing in
developing countries [10]. In the UK in 2016/17, 10.5% of
pregnant women were known to be smokers at time of de-
livery [9]. However, pregnancy is the life event which most
motivates smokers’ cessation attempts and over 50% of
pregnant smokers try stopping [8], hence smoking cessa-
tion support offered in pregnancy is likely to be especially
beneficial. In pregnancy, there is strong efficacy evidence
for using either face-to-face [11], or ‘self-help’ [12]
stop-smoking support and some evidence that financial
incentives [13] are effective as adjunctive support. Al-
though nicotine replacement therapy (NRT) is widely used
by UK pregnant smokers [14, 15], this has, at best, border-
line efficacy [16]. Poor adherence to NRT [17] and accel-
erated nicotine metabolism in pregnancy [18, 19] may
explain why NRT works well outside of [20], but not dur-
ing, pregnancy [16].
Self-help support almost doubles the odds of cessa-
tion in late pregnancy (OR 1.83, 95% CI 1.23 to 2.73)
[12]. However, self-help programmes that have been
shown to help pregnant smokers to quit were all de-
veloped before easily accessible digital technologies
became widely available [12]. Self-help text-message
smoking-cessation programmes are highly acceptable;
those trialled with non-pregnant smokers in the US
[21, 22] and UK [23] have demonstrated efficacy. Un-
fortunately, neither programme is appropriate in preg-
nancy as they make no mention of pregnancy, which,
for most pregnant smokers, is the very reason they
try quitting; consequently many pregnant smokers
would likely find much of the advice from these pro-
grammes irrelevant and ignore it. Additionally, some
of these programmes’ recommendations could be
harmful in pregnancy. For example, in pregnancy, ad-
vice about NRT, keeping fit and weight gain after
quitting are necessarily quite different from advice
given to those who are not pregnant. Although there
is a self-help, cessation-orientated text programme
available for pregnant smokers in the US [24] and
various self-help support ‘apps’ aimed at encouraging
pregnant smokers to quit, these have not yet been de-
finitively evaluated.
To remedy the lack of acceptable self-help cessation
support for pregnant smokers, we developed MiQuit, a
text-message, smoking cessation self-help support
programme for pregnant smokers. MiQuit advice is ori-
entated to pregnancy and is highly tailored to the
woman’s motivation to quit, and her attitudes, beliefs
and behaviours related to smoking. We have already
evaluated MiQuit in two randomised controlled trials
(RCTs). The first trial (n = 207) demonstrated acceptabil-
ity; 87% of recipients read every text and only 9% termi-
nated the programme early [25]. Estimated efficacy was
encouraging; 12 weeks after randomisation, biochem-
ically validated abstinence rates in MiQuit and control
groups were 12.5 and 7.8%, respectively (OR 1.68, 95%
CI 0.90 to 3.16) [25]. Subsequently, we made a few
minor modifications to MiQuit and tested this in a
second RCT which demonstrated the feasibility of
recruiting from UK National Health Service (NHS)
settings to a multi-centre RCT [26]; we recruited 407
participants from 16 trial centres in 7 months (ap-
proximately 3.5 women/centre/month). Study reten-
tion was high with only 10 withdrawals (three
revoked consent, seven withdrew after fetal deaths).
Again, estimated efficacy was encouraging; in MiQuit
and control groups, prolonged abstinence from smok-
ing, validated in late pregnancy was 5.4 and 2.0%, re-
spectively (OR 2.70, 95% CI 0.93–9.35).
Although smoking cessation rates of this size may ap-
pear small, the substantial harm caused by smoking means
that, at a population-level, such a difference would be clin-
ically important [27]. Hence, if MiQuit were to have dem-
onstrable efficacy, it could be integrated into routine
clinical practice with beneficial effects for women who
smoke in pregnancy and their infants. This trial is de-
signed to produce sufficient data such that a definitive as-
sessment of MiQuit efficacy will be possible.
Primary objective
The primary objective of this trial is to assess the effi-
cacy of the MiQuit system, when offered in addition to
Whitemore et al. Trials          (2019) 20:280 Page 2 of 13
standard behavioural support for smoking cessation in
pregnancy, by synthesising findings from this RCT with
those from the two earlier MiQuit RCTs using Trial Se-
quential Analysis (TSA) meta-analysis.
Secondary objectives
The secondary objectives for this trial are as follows:
1. To compare validated rates of prolonged smoking
cessation between 4 weeks after enrolment and 36
weeks’ gestation (late pregnancy) between MiQuit
and control groups
2. To compare rates of adverse pregnancy outcomes
between MiQuit and control groups
3. To estimate the incremental cost-effectiveness of
MiQuit when added to the usual smoking cessation
care
Methods/design
Trial design
This study is a multi-centre, two-arm, parallel-group,
single-blind, individually randomised controlled trial
testing the effectiveness of the MiQuit text-message
smoking-cessation support service in pregnant women.
Study setting
Participants will be recruited from hospital antenatal
clinics in England.
Eligibility criteria
To be eligible for the trial, participants must (1) be less
than 25 weeks pregnant, (2) have smoked at least five
cigarettes per day pre-pregnancy and have continued to
smoke at least one cigarette on a typical day during
pregnancy, (3) be aged 16 years or over, (4) agree to
accept information to assist cessation, (5) have their own
or have primary use of a mobile phone, (6) be familiar
with sending and receiving text messages, (7) be able to
understand written English (text messages are in English
only) and consent issues explained in English and (8) be
able to give informed consent.
If women express an interest in stopping smoking but
are not eligible to join the study, they will be sign-posted
to the local stop-smoking services, as part of routine
clinical practice, where these are available.
Participants should not be enrolled in another text ser-
vice to assist smoking cessation, be enrolled in any other
smoking cessation studies, or have already participated
in another MiQuit study in a previous pregnancy.
Control
Control group participants will receive a standard NHS
leaflet which provides information and advice on stopping
smoking, in addition to their usual NHS antenatal care.
Intervention
All intervention group participants will receive the same
standard NHS leaflet as control participants giving infor-
mation and advice on stopping smoking and usual NHS
antenatal care.
Additionally, they will receive MiQuit. MiQuit is a
12-week, automated, responsive, text-message, self-help
support programme which sends tailored smoking cessa-
tion support and advice to participants’ mobile phones.
MiQuit system content is tailored to 12 participant char-
acteristics collected at baseline. This can be further tai-
lored to changes in smoking status, collected via texts
sent by the participant to the MiQuit service, at two
time points during the programme. In addition, partici-
pants can text in a quit date and receive additional sup-
port tailored around this date. Participants can increase
or decrease the frequency of support that they receive at
any time by texting the keywords MORE or LESS. The
support includes motivational messages, advice about
preparing for a quit attempt, how to manage cravings
and withdrawal, dealing with trigger situations, informa-
tion about how smoking affects babies, and general en-
couragement. Depending on how participants use the
system they will receive between 69 and 121 texts over
the 12 weeks (0.8 to 1.5 texts per day). Participants can
also request on-demand instant text messages to further
support or distract them by texting one of three key-
words to the MiQuit system (QUIZ, HELP and SLIP).
Any text-message replies sent to MiQuit by participants
are charged at usual network rates or included in their
text allowance, but texts that they receive from MiQuit
are free. All likely costs to participants will be made
clear in the Participant Information Leaflet (PIL).
Adherence
Participants allocated to receive the MiQuit intervention
will receive a complete programme of text messages;
however, they can actively opt out of receiving more
messages by texting STOP to MiQuit at any time point,
thereby discontinuing their treatment. Consequently, ad-
herence could be assessed by considering whether or not
participants received a full programme or the length of
any partial programme that they received prior to ter-
minating this.
Outcomes
Primary outcome
The primary outcome for this trial will be the
self-reported smoking abstinence from 4weeks after en-
rolment until 36 weeks’ gestation, reported and biochem-
ically validated at 36 weeks by exhaled carbon monoxide
(CO) and/or saliva cotinine and anabasine estimation;
there will be no ‘grace period’ [28]. Participants who re-
port smoking no more than five cigarettes in total
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between the start of their quit attempt (within 4 weeks of
randomisation) and late pregnancy will be considered to
have quit smoking [29]. Data for this outcome will be
combined with that from previous trials in a TSA
meta-analysis – as described in the ‘Statistical methods’
section below).
Secondary outcomes
Smoking outcomes
1. Seven-day abstinence self-reported at 4 weeks;
self-reported and biochemically validated 7-day
abstinence at 36 weeks
Other outcomes for the trial are as follows:
2. Participants’ reported use of stop-smoking services
and use of NHS care whilst involved in the trial
3. Pregnancy outcomes: birth weight; gestation at birth;
or maternal or fetal death (i.e. stillbirth or
miscarriage); maternal/infant hospital admissions
4. Economic measures: EuroQol-5D-5L Level
Questionnaire (EQ-5D-5 L), costs of providing
the text-message service (staff time, costs of
maintaining text-messaging software), costs of the
usual care intervention, and wider costs of health
care admissions for mother and infant
Assignment of interventions: allocation and blinding
Enrolment and randomisation will be conducted once
the participant’s baseline data has been submitted onto a
secure online database by local research site staff. As ran-
domisation will be via the Internet, allocations will be con-
cealed from both local research site staff and participants.
Randomisation will use a computer-generated pseudo-
random code with random permuted blocks of randomly
varying size created by the York Trials Unit (YTU) in ac-
cordance with their standard operating procedure and held
on a secure server. The randomisation will be stratified by
gestation (< 16 weeks versus ≥ 16 weeks).
Following randomisation, an automated email will be
sent from the online database to the Nottingham Trial Of-
fice which will inform un-blinded central administrators,
who are not involved in participant follow-up, of the allo-
cation; a study information pack will then be sent to par-
ticipants providing them with further information on their
allocation within the trial, after which participants will no
longer be blinded to their allocation. As far as possible,
Trial Office staff who are involved in conducting the
follow-ups will remain blind to treatment allocations;
however, as participants are not blinded it is possible that
they may unintentionally reveal their allocation during a
follow-up telephone call (see later under ‘Visit 3’). The
statistician conducting analyses will have no contact with
participants and will be blinded to treatment allocations.
Identification and recruitment of participants
Information about the trial will be displayed in relevant
clinical areas and adverts in clinic environments may
also be used. Women will be identified in early preg-
nancy, as they attend hospitals for antenatal screening
(ultrasound) appointments, either by questionnaire or
from medical records. Questionnaire: a member of the
NHS care team (e.g. receptionist or local research staff )
will hand all pregnant women attending clinics a
self-complete screening questionnaire with an explana-
tory PIL attached. The PIL provides a detailed explan-
ation of the trial in order to prevent feeding participants’
expectations about receiving any particular intervention.
The screening questionnaire will identify smokers,
and those who indicate that they would like to re-
ceive self-help cessation support as part of a research
study will be asked to provide contact details, which
can be shared with the research team. Medical re-
cords: alternatively, a member of the NHS care team
will inspect clinic attenders’ records, identify those
who are potentially eligible, and provide the pregnant
smoker with a PIL.
This method of recruitment only applies to those at-
tending clinic and there are no mechanisms to be used
through which women will be recruited to the trial if
they do not attend clinic. In addition, medical records
will be examined purely to identify pregnant women
who are potentially eligible because they are recorded as
smokers; aged 16 years or over; and able to understand
written English. This is so that as many eligible partici-
pants as possible can be approached and invited to take
part in the trial. As there have been few previous similar
trials, it is not certain how a researcher could predict
propensity to consent to trial enrolment from medical
records.
There will be two recruitment methods for eligible
and interested pregnant smokers who have read and
understood the PIL. These are as follows:
1. Via staff in the NHS Trust: In centres where local
research staff are available, trial enrolment will be
offered to all eligible, interested women. Consent will
be obtained in person after women have completed
the screening questionnaire, demonstrated that they
have read and understood the PIL and confirmed
that relevant aspects of trial procedures have been
fully explained. Where possible, this will be done
whilst women are waiting in clinic so that written
informed consent can be obtained. Should the patient
need to leave the clinic before consent can be
Whitemore et al. Trials          (2019) 20:280 Page 4 of 13
obtained, a local research staff member may call and
consent the patient over the telephone as for Method
2 (below). These patients will be provided with a
PIL to take home and read and will be asked for a
convenient time to be contacted by telephone.
During the call, the trial will be fully explained and
consent provided verbally. If necessary, some women
may be called by a member of the Nottingham trial
team instead; in these instances, consent will be
obtained as for Method 2, below
2. Via Nottingham Trial Office: In centres where local
research staff are not available, depending on other
available resources, the same participant
identification methods may be used. Members
of the local NHS care team will oversee the
collation of screening questionnaires within clinic
and ensure that eligible and interested women’s
contact details have been provided. The women
would be provided with a PIL to take home and
read. The contact details will then be sent to the
Nottingham Trial Office, via either telephone call,
email, post or shared via a secure, online means; a
member of the Nottingham trial team would then
telephone potential participants, ensuring that all
aspects pertaining to trial participation are verbally
addressed prior to obtaining consent
Reasons why potential participants are not recruited
will be collected via the screening and enrolment logs.
NHS Hospital Trusts across England, with varying
smoking rates amongst pregnant women, will be used as
recruitment sites.
Withdrawal of participants from intervention or
assessments
Participants may be withdrawn from the trial either at
their own request or at the discretion of the investigator.
Participants who experience miscarriage or fetal death
may be advised to withdraw from the trial. A list of par-
ticipants due to be followed up will be sent to site staff
prior to their scheduled visit. This will assist in identify-
ing any participants whose medical records show them
to have experienced an event which might make
follow-up distressing, e.g. miscarriage. This approach
was used in the latter stages of the pilot trial [30] and it
was found that most participants were agreeable to dis-
cussion of smoking status, irrespective of whether mis-
carriage had occurred, provided that the researcher
conducting follow-up was appropriately sensitive.
Participant timeline and data collection
Figure 1 describes the participant assessments at each
stage. Figure 2 provides an overview of the study design
and measurement time points.
Pre-screen
All potential participants will be identified via a brief
screening questionnaire, accompanied by a PIL.
Recruitment Method 1: For recruitment by this
method local research staff working within the partici-
pating acute NHS Trust will explain all aspects of the
trial and will counter-sign the consent form. The partici-
pant will be able to provide either written informed con-
sent (face-to-face) or verbal informed consent
(telephone).
Recruitment Method 2: For recruitment by this
method a member of the Nottingham trial study team
will be required to complete the consent form to indi-
cate that all relevant issues have been addressed and the
patient is eligible to be recruited into the trial. The study
team member will sign the participant’s consent form
and mark it as being completed via telephone.
Participants will be asked to provide written informed
consent for the potential collection of an exhaled breath
and/or saliva sample after their 36-week gestation
follow-up by a member of the local research staff either
during a hospital visit or by a visit to their home. How-
ever, they will be informed that samples would only be
required if they were to report 7-day abstinence from
smoking at this time point.
All participants will be provided with clear information
about how to withdraw consent using a Freepost post-
card (provided to all participants in their study informa-
tion pack), text, email or telephone. In a similar trial in
which we provided similar methods to facilitate in-
formed consent, less than 60 participants (from over
2500) withdrew consent after enrolment [31].
Visit 1 – Baseline
After giving informed consent, participants will be asked
to complete a baseline questionnaire in person or via
telephone with local research staff (recruitment Method
1) or with a Nottingham trial team member by tele-
phone (recruitment Method 2).
The researcher will enter the participant details on the
electronic database and randomise them to intervention
(MiQuit) or control using the York Trials Unit’s
web-based service. The researcher will remain blind to
participants’ treatment allocations. For participants in ei-
ther trial arm, a specific information leaflet describing
only details of procedures employed within that arm will
be generated only after randomisation. This is to minim-
ise the number of participants who may wish to with-
draw due to dissatisfaction with their treatment
allocation and is and sent to them by a non-blinded
member of the trial team who is not involved in
follow-up. All participants will also be sent a standard
NHS leaflet giving advice on stopping smoking during
pregnancy, contact details for participants who have
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questions about trial involvement and information on
how to withdraw if they change their mind. The PIL, in-
formation sheets and consent form will be available in
English only as understanding of English is required to
receive the MiQuit intervention.
Follow-up contacts will use a blend of postal, tele-
phone, email/web and SMS text-messaging reminders to
elicit maximal response rates.
Visit 2 – 4-week follow-up
At 4 weeks after randomisation, participants will be con-
tacted via telephone in order to assess smoking status,
and obtain quality of life information (EQ-5D-5 L) in the
period since randomisation. This visit will, in general, be
performed via telephone by a member of the study team
at the co-ordinating centre, blind to treatment alloca-
tion. However, should the study team be unable to con-
tact the participant by telephone other methods will be
used in an attempt to elicit the best response. These in-
clude; posting a short questionnaire with explanatory
letter and pre-paid return envelope, and/or emailing a
link which allows web-based completion.
Whilst it is theoretically possible that members of
the Nottingham Trial Office team who speak to par-
ticipants at the 4-week follow-up could become aware
of participants’ treatment group and hence un-blinded
for data collection at the late-pregnancy follow-up
(Visit 3), we found that this was not an issue in the
pilot study due to the time lapse between follow-up
points. Additionally, as in the pilot trial, a number of
different researchers will be involved in collecting
follow-up data and, therefore, different researchers
within the trial team may be collecting an individual’s
data at Visit 2 (4 weeks after randomisation) and Visit
3 (36-week gestation) follow-ups.
Visit 3 – Late pregnancy/postnatal follow-up
At 36 weeks’ gestation, participants will be asked to
complete a questionnaire (data to be collected up to 10
weeks after estimated delivery date will be acceptable for
Fig. 1 Schedule of participant assessments
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use). This will include quality of life information
(EQ-5D-5L), number of quit attempts lasting more than
24 h, measures of smoking behaviour, attitudinal/behav-
ioural information, and use of NHS smoking cessation
support and participants’ ratings of the intervention
(MiQuit arm only). As for the 4-week visit, this visit will
be performed mainly via telephone by a member of the
study team at the co-ordinating centre, blind to treat-
ment allocation. As for the 4-week visit, previously de-
scribed alternative methods will be employed to elicit
the best response rate.
It is recognised that asking about the intervention
at follow-up will result in the researcher who con-
ducts the late-pregnancy follow-up becoming
un-blinded. To ensure that this has minimal impact
on the follow-up data obtained, the participants will
be asked items about the intervention at the end of
the interview/questionnaire starting with the question:
‘Did you receive any stop-smoking text messages from
the study team?’
At approximately 36 weeks’ gestation (Visit 3),
participants will be asked basic questions about their
recall of and use of advice in texts sent; however,
this is a process measure to check that the in-
tervention was received rather than a measure of
adherence.
Visit 4 – Validation of smoking status
This visit will be undertaken either face-to-face or by
post, as soon as possible after Visit 3 for all participants
Fig. 2 Study design, measures and estimated sample
Whitemore et al. Trials          (2019) 20:280 Page 7 of 13
who at this visit, report abstinence from smoking for the
previous 7 days and the aim is to biochemically validate
participants’ reported abstinence. Prior to contacting the
participant for their Visit 3 follow-up the Nottingham
Trial Office will ask the appropriate recruiting site to as-
certain whether the participant will be attending a hos-
pital growth scan at around 36 weeks’ gestation. These
scans are used in a number of NHS Trusts for pregnant
women who are known to be smoking, or to have
smoked prior to their pregnancy. When participants at-
tend hospital for such scans, the Nottingham Trial Of-
fice will try to arrange Visit 4, if required, to coincide
with this.
Participants will be asked to report their smoking sta-
tus, recent use of nicotine replacement therapies and/or
e-cigarettes. Reported smoking abstinence will be vali-
dated using exhaled CO, and/or saliva samples will be
taken for cotinine (a nicotine metabolite) [32] and ana-
basine assays. Anabasine is a tobacco-specific metabolite
which reflects tobacco smoke exposure, and so can dis-
tinguish this from use of e-cigarettes or nicotine replace-
ment therapy. Exhaled CO will be measured using a
validated, hand-held CO monitor and can only be ad-
ministered by a researcher during a face-to-face visit.
Where possible both exhaled CO and the relevant saliva
assay will be used together as validation; however, if a
valid sample cannot be obtained for one method, the use
of the other method alone would be deemed sufficient.
Where it is not possible to arrange a face-to-face valid-
ation visit with the participant in either their home or
during a hospital visit, a saliva sample kit will be posted
to them; they will be asked to provide a saliva sample
and to post this back to the Nottingham Trial Office
using a secure, pre-paid Royal Mail SafeBox.
Cut-off points for biochemical verification will be de-
termined according to the latest evidence, but defined
abstinence is likely to be in the region of < 9 ppm for
CO readings and < 10 ng/ml for salivary cotinine [33].
Duration of the trial
It is anticipated that the total duration of the study will
be 36 months. This will include 18months of recruit-
ment and 9months of follow-up. Participants of up to
25 weeks’ gestation (24 weeks and 6 days) will be enrolled
and late pregnancy outcome ascertainment is intended
to be at 36 weeks’ gestation, or at latest, within 2 weeks
of birth. However, if outcome data becomes available
after this point, we will permit it to be used in analyses
provided the timing of data collection is no later than
10 weeks after the estimated due date. Assuming that
some individuals might be recruited at their first ante-
natal visit, at around 10 weeks’ gestation, the maximum
possible duration of a participant’s involvement in the
trial is, therefore, approximately 40 weeks.
End of the trial
The end of the trial will be when the late pregnancy out-
come has been ascertained for the final participant or it
is too long after this participant’s estimated delivery date
for such information, if collected, to be used.
Participant stipends and payments
All participants will receive a £5 high street shopping
voucher at each of the four visits to recognise the time
taken for their participation in the trial when completing
questionnaires. Where all of the first three visits are
completed, participants will receive a fourth high street
shopping voucher to the value of £10. In addition, a £15
high street shopping voucher will be sent to those par-
ticipants who provide a saliva sample and/or breath
sample during the validation Visit 4 (if required).
Statistical methods
Sample size and justification
We already have data from two very similar RCTs [25,
26] and the study design for this trial is identical to the
larger of these [26]. Consequently, it was considered that
the most resource-efficient approach would be to
complete a third trial which recruits sufficient partici-
pants such that when data from all three RCTs is pooled,
this gives a definitive answer about the efficacy of the
MiQuit service. We pooled data from the previous trials
and used TSA meta-analysis [34] to estimate that, from
the proposed RCT we need an additional 692 partici-
pants for a pooled analysis of all three RCTs to provide
definitive findings regarding effectiveness. However,
using pilot study data [26] it is also possible to perform
a traditional sample size calculation which determines a
95% confidence interval width which would exclude a
minimum important difference between the two inter-
vention groups [35]. Additionally, based on the quit rates
from the pilot study (intervention group 5.4% and con-
trol group 2%) [26], the proposed RCT with a sample
size of 346 participants per treatment arm would, if con-
sidered on its own, enable a 95% confidence interval for
the difference in quit rates to be estimated to within a
precision of ± 3%. Therefore, if this trial observed a 3%
difference or greater in quit rates our 95% confidence in-
tervals would not pass through zero.
Trial sequential analysis meta-analysis (data synthesis)
Data from this RCT and the two earlier RCTs [25, 26]
will be combined in a meta-analysis, using the TSA
methods [34] to determine whether or not MiQuit is ef-
fective for smoking cessation in pregnancy.
Trial analysis (using data from this RCT only): Ana-
lyses, undertaken in Stata v13 or later, will follow the
principles of intention-to-treat with outcomes analysed
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according to randomised groups irrespective of devia-
tions based on non-compliance unless otherwise speci-
fied. All outcomes will be analysed once at the trial’s
conclusion. Significance tests will be two-sided at the 5%
level unless otherwise stated. Parameter estimates will be
presented with associated 95% confidence intervals and
p values as appropriate
Smoking outcomes: Where smoking outcome data is
missing, we will assume women to be smoking. We will
compare smoking outcomes between intervention and
usual care groups at the 36-week gestation follow-up
point using a penalised logistic regression model adjust-
ing for stratification factors and also potential con-
founders as fixed-effect covariates. A sensitivity analysis
using multiple imputation will assess the robustness of
the results to variation in the missing data assumptions.
We will also compare the other smoking-related out-
comes between the trial arms using a similar model to
the primary analysis. A Complier-Average Causal Effects
(CACE) analysis for the primary outcome will be con-
ducted to obtain unbiased estimates of the intervention
efficacy with full compliance. Other secondary outcomes
will be summarised descriptively by treatment group and
comparisons will be made between the groups using ap-
propriate regression techniques.
Economic analysis The economic analysis of the
MiQuit 3 trial comprises two components. A ‘within--
trial’ incremental cost-effectiveness analysis will be based
on an ‘end-of-pregnancy’ horizon using ‘cost-per-quitter’
as an outcome measure. Intervention costs will be pro-
spectively recorded alongside the trial. These include
costs of providing the text-message service (staff time,
costs of maintaining text-messaging software). Costs of
usual care are also recorded as the comparator. The ana-
lysis combines intervention costs and wider health care
costs with the number of quitters to calculate the cost
per quitter of the MiQuit intervention over and above
usual care. We will also collect EQ-5D-5 L at baseline
and each follow-up to enable to computation of
Quality-adjusted Life Years (QALYs) [36].
The longer-term economic evaluation uses a previously
developed model [37–39] and pooled efficacy parameters
generated by TSA meta-analysis to conduct a cost-utility
analysis with maternal and infant lifetime-horizons to esti-
mate the incremental cost per additional QALY. Costs
and outcomes will be discounted at 3.5% as recommended
by National Institute for Health and Care Excellence
(NICE) guidance [40]. We will explore the impact of un-
certainty with the use of non-parametric bootstrapping
for the ‘within-trial’ analysis and probabilistic sensitivity
analysis in the model [41, 42]. This analysis is essential for
the MiQuit 3 trial as many adverse health effects of smok-
ing in pregnancy occur beyond the time horizon of final
trial follow-up. Long-run cost-effectiveness estimates can
be compared with cost per QALY benchmarks to establish
the value for money of MiQuit compared to competing
claims for health care resources.
Data management
Data will be entered electronically into a trial-specific
database. Only local research staff and the study team at
the Nottingham Trial Office will have database access,
which permits them to make new entries. Access to par-
ticipant personal data already recorded on the database
will be restricted to Nottingham trial staff and the York
Trials Unit. To ensure anonymisation, at randomisation,
each participant will be assigned a unique trial identity
code number for use on all trial documents and the elec-
tronic database. The database will be maintained on a
server located within the York Trials Unit, University of
York. The database has a regular back-up routine, and
will be password-protected. Anonymised data, which are
sent to the MiQuit service for tailoring of intervention
group participants, will be held on a secure server within
the Institute of Public Health at the University of Cam-
bridge. Only authorised staff will have access to trial
documentation other than for the regulatory require-
ments. All trial staff and investigators will endeavour to
protect the rights of the trial’s participants to privacy
and informed consent, and will adhere to the Data Pro-
tection Act, 1998. Electronic data will be backed up
every 24 h to both local and remote media in encrypted
format.
Monitoring of trial data will include confirmation of
informed consent; source data verification; data storage
and data transfer procedures; local quality control
checks and procedures, back-up and disaster recovery of
any local databases and validation of data manipulation.
The trial manager, or where required, a nominated des-
ignee of the sponsor, will carry out monitoring of trial
data as an on-going activity. In compliance with the
International Conference on Harmonisation/Good Clin-
ical Practice
(ICH/GCP) guidelines, regulations and in accordance
with the University of Nottingham Research Code of
Conduct and Research Ethics, the chief or local principal
investigator will maintain all records and documents re-
garding the conduct of the study. These will be retained
for at least 7 years or for longer if required. The Trial
Master File (TMF) and trial documents held by the chief
investigator (CI) on behalf of the sponsor will be finally
archived at secure archive facilities at the University of
Nottingham.
The study archive will include all trial databases and
associated meta-data encryption codes. However, the
trial database will be designed by the York Trials Unit
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using bespoke software, which is not supported outside
of the York Trials Unit. Therefore, for data to remain re-
trievable and potentially useful after the end of the study
any data stored in databases created at York will be ar-
chived there. The Department of Health Sciences, in
which York Trials Unit is based at the University of
York, has a back-up procedure approved by auditors for
disaster recovery. There will be a separate archival of
electronic data performed at the end of the trial to safe-
guard the data, and in accordance with regulatory
requirements.
Transport, storage and analysis of saliva samples
Saliva samples will be collected from consenting partici-
pants who have reported abstinence from smoking,
using the methods previously described under Visits 3
and 4. Samples will be obtained using clean salivettes;
this involves participants placing sterile swabs under
their tongues until moist for up to 5 min and then pla-
cing the swab into a sterile vessel. Samples will be la-
belled and held within Nottingham Health Science
Biobank (NHSB) in a secure freezer storage unit (− 80 °
C) according to approved protocols. Where local re-
search staff obtain samples, these will be posted by the
study team in suitable packaging, and when received, the
study team will transfer them to NHSB. Saliva and ana-
basine samples are stable at ambient temperatures for
several days. Nottingham Health Science Biobank has
been given full approval by the Human Tissue Authority
(HTA) to be a full licence holder, meeting all legislation
requirements.
NHSB will arrange transportation of samples by cour-
ier to ABS Laboratories Ltd., Hertfordshire, UK for ana-
lysis in a single-batch shipment. The shipment will
contain a complete inventory of all samples, along with
the name of the person responsible for sending the sam-
ples. The master database to link all samples will be held
by the Nottingham study team in a password-encrypted
file. The laboratory will estimate salivary cotinine and
anabasine levels using a quantitative enzyme immuno-
assay technique (EIA).
Once the analysis has been completed the saliva sam-
ples will be destroyed in accordance with the Human
Tissue Act 2004, this will only occur once the study
team has received the results and has analysed the data
to ensure that all samples remain in a normal range and
do not require retesting.
Dissemination
Results will be written up for publication in peer-
reviewed journals and disseminated at local, national
and international meetings where appropriate. Papers
describing the key findings will be submitted within 12
months of the trial completion. A lay summary will be
produced and distributed to those participants who have
indicated that they would like to receive a copy, and
other interested parties. Participants will not be identi-
fied in any publications or presentations resulting from
this study.
User and public involvement
A Public and Patient Involvement (PPI) representative
has contributed to this protocol, to trial documents and
to the development of the intervention.
Indemnity
Insurance and indemnity for trial participants and trial
staff is covered within the NHS Indemnity Arrange-
ments for clinical negligence claims in the NHS, issued
under cover of Health Service Guidelines (HSG) (96)48.
There are no special compensation arrangements, but
trial participants may have recourse through the NHS
complaints procedures.
The University of Nottingham as research sponsor in-
demnifies its staff, research participants and research
protocols with both public liability insurance and clinical
trials insurance. These policies include provision for in-
demnity in the event of a successful litigious claim for
proven non-negligent harm.
Trial management
The CI has overall responsibility for the study and will
oversee all study management. The Trial Management
Group (TMG) will be responsible for the day-to-day
running of the trial. The TMG will meet on a monthly
basis and will be supported by and reporting to a Trial
Steering Committee (TSC), which will meet as and when
required; a separate Data Monitoring and Ethics Com-
mittee is not judged necessary, as we cannot envisage
the intervention having the potential to harm partici-
pants. The names of TSC members and their roles will
be stated on the University of Nottingham’s TSC Charter
(v1.2 October 2014) and the TSC Membership Agree-
ment (v1.1 October 2014).
Trial co-ordination, with respect to recruitment and
follow-up will be managed centrally by the study team
based in Nottingham, led by a trial manager and guided
by the TMG.
Trial co-ordination, with respect to data management
and analyses will be managed by the York Trials Unit
team, again guided by the TMG. The Nottingham trial
manager will be responsible for overall co-ordination
across the lead sites for management of recruitment
(Nottingham) and data (York).
The Cambridge research team will manage a server
hosting the MiQuit intervention; however, the data cus-
todian will be the CI.
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Sponsor
The trial is sponsored by the University of Nottingham.
Discussion
Once completed, the results from this definitive trial
should provide sufficient data to determine, using Trial
Sequential Analysis (TSA) meta-analysis, whether or not
MiQuit shows efficacy when offered in addition to
standard behavioural support for smoking cessation in
pregnancy. TSA methods have previously been used to
assess the likelihood that positive or negative findings
from traditional meta-analyses are valid and we believe
that our proposed use of TSA meta-analysis methods is
novel.
TSA is a method for pooling RCT data which quanti-
fies the statistical reliability of data in a cumulative
meta-analysis adjusting significance levels on accumulat-
ing data for small numbers and repetitive testing [34].
This method is useful for assessing intervention efficacy
when few, relatively small trials are available. We have
data from two smaller trials which randomised 614 par-
ticipants, [25, 26] and combining data from the add-
itional 692 participants recruited in this RCT with these
previously collected data in a TSA meta-analysis will de-
rive a pooled estimate for MiQuit efficacy. This third
RCT has an almost identical design and outcomes to
earlier ones; if there were substantial differences in trial
protocols or outcomes, TSA meta-analysis might not
have been possible. Additionally, this approach might
not have been appropriate if the intervention was poten-
tially harmful to women or their babies because, in that
instance either a full trial or a TSA meta-analysis might
have needed sufficient power to also detect whether or
not MiQuit caused adverse outcomes. However, it is dif-
ficult to foresee how MiQuit could be harmful and so
this does not apply.
Apart from using other forms of text-message support,
MiQuit 3 trial participants will be free to access what-
ever NHS support with stopping smoking is available in
their locality. As such, if MiQuit does prove to have a
positive effect on cessation, this will be additional to that
which participants have obtained via usual NHS means
and so, adjunctive to standard smoking cessation sup-
port provided during pregnancy. Therefore, if it is
proven to work, MiQuit could be disseminated to preg-
nant smokers either alongside usual stop-smoking sup-
port or in parallel to this in the expectation of it having
positive effects on women’s smoking. This would also be
relatively easy as MiQuit is fully adapted for ‘self-initia-
tion’ and users can activate the service after finding it on
the web [43], or after seeing a leaflet [44]. Addition-
ally, MiQuit is such a cheap intervention that if it
has even a very small impact on cessation it could
prove very cost-effective and so the proposed,
longer-term, model-based economic evaluation which
will follow the RCT is likely to be of particular inter-
est to policy-makers (Additional file 1).
Trial status
Recruitment began in November 2017, with the first par-
ticipant randomised on 4 December 2017. At the time of
the manuscript submission, the trial was still recruiting
with 455 participants recruited by 27 April 2018. It is
anticipated that recruitment will be completed by
September 2018. This article is based on protocol ver-
sion 1.1, 29 September 2017.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for Clinical
Trials (SPIRIT) 2013 Checklist: recommended items to address in a clinical
trial protocol and related documents*. (DOC 120 kb)
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